These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20679350)

  • 1. Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma.
    Kasahara K; Arao T; Sakai K; Matsumoto K; Sakai A; Kimura H; Sone T; Horiike A; Nishio M; Ohira T; Ikeda N; Yamanaka T; Saijo N; Nishio K
    Clin Cancer Res; 2010 Sep; 16(18):4616-24. PubMed ID: 20679350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
    Yamaguchi H; Soda H; Nakamura Y; Takasu M; Tomonaga N; Nakano H; Doi S; Nakatomi K; Nagashima S; Takatani H; Fukuda M; Hayashi T; Tsukamoto K; Kohno S
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):331-8. PubMed ID: 20401612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors.
    Cohen V; Agulnik JS; Ang C; Kasymjanova G; Batist G; Small D; Brandao G; Chong G; Miller WH
    Cancer; 2010 Sep; 116(18):4309-17. PubMed ID: 20549828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of α1-antitrypsin as a potential prognostic biomarker for advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors by proteomic analysis.
    Zhao W; Yang Z; Liu X; Tian Q; Lv Y; Liang Y; Li C; Gao X; Chen L
    J Int Med Res; 2013 Jun; 41(3):573-83. PubMed ID: 23613495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
    Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
    Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
    Bonomi PD; Buckingham L; Coon J
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reaction of plasma adiponectin level in non-small cell lung cancer patients treated with EGFR-TKIs.
    Umekawa K; Kimura T; Kudoh S; Suzumura T; Nagata M; Mitsuoka S; Matsuura K; Oka T; Yoshimura N; Kira Y; Hirata K
    Osaka City Med J; 2013 Jun; 59(1):53-60. PubMed ID: 23909081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
    John T; Liu G; Tsao MS
    Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients.
    Wang S; Han X; Hu X; Wang X; Zhao L; Tang L; Feng Y; Wu D; Sun Y; Shi Y
    Clin Chim Acta; 2014 Mar; 430():63-70. PubMed ID: 24378285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classification of Epidermal Growth Factor Receptor Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV Non-Small-Cell Lung Cancer.
    Yang L; Tang C; Xu B; Wang W; Li J; Li X; Qin H; Gao H; He K; Song S; Liu X
    PLoS One; 2015; 10(6):e0128970. PubMed ID: 26047516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reaction of plasma hepatocyte growth factor levels in non-small cell lung cancer patients treated with EGFR-TKIs.
    Tanaka H; Kimura T; Kudoh S; Mitsuoka S; Watanabe T; Suzumura T; Tachibana K; Noguchi M; Yano S; Hirata K
    Int J Cancer; 2011 Sep; 129(6):1410-6. PubMed ID: 21128242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.
    Kotsakis A; Georgoulias V
    Expert Opin Pharmacother; 2010 Oct; 11(14):2363-89. PubMed ID: 20586711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma.
    Nishio M; Yamanaka T; Matsumoto K; Kimura H; Sakai K; Sakai A; Sone T; Horiike A; Koizumi F; Kasahara K; Ohira T; Ikeda N; Saijo N; Arao T; Nishio K
    J Thorac Oncol; 2011 Nov; 6(11):1889-94. PubMed ID: 21964526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities.
    da Cunha Santos G; Saieg MA; Geddie W; Leighl N
    Cancer Cytopathol; 2011 Apr; 119(2):80-91. PubMed ID: 21400669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer.
    Vollebergh MA; Kappers I; Klomp HM; Buning-Kager JC; Korse CM; Hauptmann M; de Visser KE; van den Heuvel MM; Linn SC
    J Thorac Oncol; 2010 Dec; 5(12):1939-48. PubMed ID: 21102259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor mutation in gastric cancer.
    Liu Z; Liu L; Li M; Wang Z; Feng L; Zhang Q; Cheng S; Lu S
    Pathology; 2011 Apr; 43(3):234-8. PubMed ID: 21436633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure.
    Shukuya T; Takahashi T; Naito T; Kaira R; Ono A; Nakamura Y; Tsuya A; Kenmotsu H; Murakami H; Harada H; Mitsuya K; Endo M; Nakasu Y; Takahashi K; Yamamoto N
    Lung Cancer; 2011 Dec; 74(3):457-61. PubMed ID: 21571388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of plasma HGF level for monitoring acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
    Umeguchi H; Sueoka-Aragane N; Kobayashi N; Nakamura T; Sato A; Takeda Y; Hayashi S; Sueoka E; Kimura S
    Oncol Rep; 2015 Jan; 33(1):391-6. PubMed ID: 25338771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGF receptor in lung cancer: a successful story of targeted therapy.
    Domingo G; Perez CA; Velez M; Cudris J; Raez LE; Santos ES
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1577-87. PubMed ID: 20942629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.